ScreenerHero

AZTR Azitra, Inc.

AMEX · US · Healthcare · Biotechnology · azitrainc.com
0.1320USD+1.54%Mkt Cap: 8.00M $P/E: —

Azitra, Inc., an early-stage clinical biopharmaceutical company, develops therapies for precision dermatology using engineered proteins and topical live biotherapeutic products to treat skin diseases in the United States…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap8.00M USD
Enterprise Value1.56M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-10.96M USD
Revenue/Share—
Last Price0.1320 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees13
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-0.25
PEG—
EV/EBITDA-0.13
EV/Revenue—
P/S—
P/B1.07
EPS (TTM)-0.28
EPS (Forward)-0.52
52W Range
0.10003% of range1.090
52W High1.090 USD
52W Low0.1000 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-288.21%
ROA-218.00%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-11.22M USD
CapEx (TTM)186.06K USD
FCF Margin—
FCF Yield-90.53%
Net Debt-6.32M USD
Net Debt/EBITDA0.52
Balance Sheet
Debt/Equity0.11
Current Ratio4.86
Quick Ratio4.49
Book Value/Sh0.12 USD
Cash/Share0.11 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split15:100
Split DateAug 21, 2025
Analyst Consensus
Rating2.0 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)0.6700 USD
Upside (mean)+407.6%
Target Range0.3400 USD – 1.000 USD
0.3400+407.6% to mean1.000
# Analysts2
Ownership
Shares Out.60.60M
Float51.25M
Insiders7.59%
Institutions32.04%
Short Interest
Short Ratio0.3d
Short % Float1.28%
Short % Out.1.16%
Shares Short701.35K
Short (prev mo.)20.86K
Technical
SMA 500.1532 (-13.8%)
SMA 2000.2017 (-34.6%)
Beta-1.04
S&P 52W Chg16.45%
Avg Vol (30d)994.86K
Avg Vol (10d)921.66K
Technical Indicators
RSI (14)41.2
MACD-0.0054
MACD Signal-0.0012
MACD Hist.-0.0042
BB Upper0.1973 USD
BB Middle0.1579 USD
BB Lower0.1185 USD
BB Width49.89%
ATR (14)0.0136 USD
Vol Ratio (20d)0.27x